---
layout: default
title: Dorzolamide
description: "Dorzolamide 的老藥新用潛力分析。中等證據等級 L3，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 62
evidence_level: L1
indication_count: 10
---

# Dorzolamide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L3</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dorzolamide：從高眼壓症到原發性遺傳性青光眼

## 一句話總結

<p class="key-answer" data-question="Dorzolamide 可以用於治療什麼新適應症？">
Dorzolamide 原本用於治療高眼壓症及廣角性青光眼。
TxGNN 模型預測它可能對**原發性遺傳性青光眼 (primary hereditary glaucoma)** 有效，
目前有 **1 個臨床試驗**和多項開角性青光眼研究支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 高眼壓症、廣角性青光眼 |
| 預測新適應症 | open-angle glaucoma、primary hereditary glaucoma、hypotrichosis simplex of the scalp、congenital hypotrichosis milia、alopecia、diffuse alopecia areata、glaucoma 1, open angle、open angle glaucoma、congestive heart failure、acute pulmonary heart disease |
| TxGNN 預測分數 | 99.99% |
| 證據等級 | L3 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Proceed with Guardrails |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. primary hereditary glaucoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>
<p>Dorzolamide 是碳酸酐酶抑制劑，透過抑制眼內睫狀體的碳酸酐酶 II 型，</p>
<p>減少房水分泌，從而降低眼內壓。其在開角性青光眼中的療效已被證實，</p>
<p>而原發性遺傳性青光眼雖然病因涉及基因突變，但眼壓升高仍是主要致病機轉，</p>
<p>因此降眼壓治療在機轉上具有合理性。</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>此預測基於藥物的作用機轉，與現有臨床證據方向一致。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01527682" target="_blank">NCT01527682</a></td><td>PHASE2</td><td>COMPLETED</td><td>37</td><td>Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor f...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. alopecia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15091328/" target="_blank">15091328</a></td><td>2004</td><td>Article</td><td>Veterinary ophthalmology</td><td>Uveodermatologic syndrome in a Brazilian Fila dog.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. diffuse alopecia areata</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. glaucoma 1, open angle</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（41 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00333125" target="_blank">NCT00333125</a></td><td>PHASE3</td><td>COMPLETED</td><td>319</td><td>A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01887223" target="_blank">NCT01887223</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Tre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01896180" target="_blank">NCT01896180</a></td><td>PHASE2</td><td>COMPLETED</td><td>63</td><td>A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Lat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00314171" target="_blank">NCT00314171</a></td><td>PHASE3</td><td>COMPLETED</td><td>437</td><td>A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertensio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822081" target="_blank">NCT00822081</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00546286" target="_blank">NCT00546286</a></td><td>PHASE3</td><td>COMPLETED</td><td>170</td><td>A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03257813" target="_blank">NCT03257813</a></td><td>PHASE3</td><td>COMPLETED</td><td>60</td><td>Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00397241" target="_blank">NCT00397241</a></td><td>PHASE4</td><td>COMPLETED</td><td>33</td><td>24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00273455" target="_blank">NCT00273455</a></td><td>PHASE4</td><td>COMPLETED</td><td>34</td><td>Lumigan Versus Cosopt</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00767481" target="_blank">NCT00767481</a></td><td>PHASE3</td><td>TERMINATED</td><td>6</td><td>1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03193333" target="_blank">NCT03193333</a></td><td>PHASE3</td><td>TERMINATED</td><td>51</td><td>A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00991822" target="_blank">NCT00991822</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>160</td><td>A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Dis...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00761995" target="_blank">NCT00761995</a></td><td>PHASE4</td><td>COMPLETED</td><td>200</td><td>Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Redu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00576342" target="_blank">NCT00576342</a></td><td>PHASE3</td><td>COMPLETED</td><td>129</td><td>A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Gl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01471158" target="_blank">NCT01471158</a></td><td>PHASE4</td><td>COMPLETED</td><td>120</td><td>Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Pati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00957190" target="_blank">NCT00957190</a></td><td>PHASE4</td><td>COMPLETED</td><td>25</td><td>Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctua...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05973305" target="_blank">NCT05973305</a></td><td>PHASE3</td><td>COMPLETED</td><td>118</td><td>A Randomized, Open-label, Controlled, Comparative Study of Efficacy and Safety o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06883123" target="_blank">NCT06883123</a></td><td>PHASE4</td><td>RECRUITING</td><td>70</td><td>Efficacy and Tolerability of Simbrinza and Rocklatan vs. Cosopt</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02802137" target="_blank">NCT02802137</a></td><td>PHASE4</td><td>COMPLETED</td><td>43</td><td>24-hour Efficacy and Ocular Surface Health With PF Tafluprost and Combined Thera...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00824824" target="_blank">NCT00824824</a></td><td>NA</td><td>COMPLETED</td><td>21</td><td>Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary O...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05973318" target="_blank">NCT05973318</a></td><td>PHASE3</td><td>COMPLETED</td><td>110</td><td>An Open-label, Randomized, Controlled, Comparative Efficacy and Safety Study of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02325518" target="_blank">NCT02325518</a></td><td>PHASE4</td><td>COMPLETED</td><td>218</td><td>The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06369077" target="_blank">NCT06369077</a></td><td>PHASE4</td><td>TERMINATED</td><td>36</td><td>Cross-over Comparison of Latanoprost QOD With Dor-tim QAM to Tim-brim-dor-bim(At...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02053298" target="_blank">NCT02053298</a></td><td>PHASE4</td><td>COMPLETED</td><td>30</td><td>Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822055" target="_blank">NCT00822055</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03966560" target="_blank">NCT03966560</a></td><td>PHASE4</td><td>COMPLETED</td><td>96</td><td>Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Pr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00273442" target="_blank">NCT00273442</a></td><td>PHASE4</td><td>COMPLETED</td><td>60</td><td>Assessing Cosopt Switch Patients</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03966365" target="_blank">NCT03966365</a></td><td>PHASE1</td><td>COMPLETED</td><td>24</td><td>Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Preservat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04673604" target="_blank">NCT04673604</a></td><td>NA</td><td>COMPLETED</td><td>42</td><td>Changing From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01340014" target="_blank">NCT01340014</a></td><td>PHASE4</td><td>COMPLETED</td><td>112</td><td>Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06177678" target="_blank">NCT06177678</a></td><td>PHASE2</td><td>UNKNOWN</td><td>60</td><td>A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04702789" target="_blank">NCT04702789</a></td><td>PHASE4</td><td>TERMINATED</td><td>28</td><td>Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00815373" target="_blank">NCT00815373</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01062971" target="_blank">NCT01062971</a></td><td>PHASE2</td><td>COMPLETED</td><td>124</td><td>Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00108017" target="_blank">NCT00108017</a></td><td>PHASE3</td><td>COMPLETED</td><td>330</td><td>Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurna...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01145898" target="_blank">NCT01145898</a></td><td>N/A</td><td>COMPLETED</td><td>56</td><td>Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Pros...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00471068" target="_blank">NCT00471068</a></td><td>PHASE4</td><td>TERMINATED</td><td>46</td><td>Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertensi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00972257" target="_blank">NCT00972257</a></td><td>PHASE4</td><td>COMPLETED</td><td>64</td><td>Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00878917" target="_blank">NCT00878917</a></td><td>PHASE3</td><td>COMPLETED</td><td>32</td><td>Randomized, Double-Masked, Active Controlled, Crossover Phase III Equivalence St...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00273481" target="_blank">NCT00273481</a></td><td>PHASE4</td><td>COMPLETED</td><td>33</td><td>Cosopt Versus Xalacom</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00675207" target="_blank">NCT00675207</a></td><td>PHASE4</td><td>COMPLETED</td><td>120</td><td>Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as A...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26526633/" target="_blank">26526633</a></td><td>2016</td><td>Article</td><td>Ophthalmology</td><td>Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glauc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39569785/" target="_blank">39569785</a></td><td>2024</td><td>Article</td><td>Vestnik oftalmologii</td><td>[Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37425383/" target="_blank">37425383</a></td><td>2023</td><td>Article</td><td>The Malaysian journal of medic</td><td>Comparing the Effectiveness and Adherence between Fixed and Non-Fixed Dorzolamid...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39677168/" target="_blank">39677168</a></td><td>2024</td><td>Article</td><td>Cureus</td><td>Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34447609/" target="_blank">34447609</a></td><td>2021</td><td>Article</td><td>Journal of drug assessment</td><td>Efficacy and safety of timolol-dorzolamide fixed-combination three times a day v...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27913991/" target="_blank">27913991</a></td><td>2017</td><td>Article</td><td>Advances in therapy</td><td>24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17943780/" target="_blank">17943780</a></td><td>2007</td><td>Article</td><td>The Cochrane database of syste</td><td>Medical interventions for primary open angle glaucoma and ocular hypertension.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22207522/" target="_blank">22207522</a></td><td>2011</td><td>Article</td><td>International ophthalmology</td><td>Comparison of fixed combinations of dorzolamide/timolol and brimonidine/timolol ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33397657/" target="_blank">33397657</a></td><td>2022</td><td>Article</td><td>The British journal of ophthal</td><td>Short-term efficacy of latanoprostene bunod for the treatment of open-angle glau...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16519552/" target="_blank">16519552</a></td><td>2006</td><td>Article</td><td>PharmacoEconomics</td><td>Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11200308/" target="_blank">11200308</a></td><td>2000</td><td>Article</td><td>Drugs &amp; aging</td><td>Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of ope...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37164404/" target="_blank">37164404</a></td><td>2023</td><td>Article</td><td>Klinische Monatsblatter fur Au</td><td>Primary Open-Angle Glaucoma Progression in Glaucoma Patients with Unchanged Topi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18364402/" target="_blank">18364402</a></td><td>2008</td><td>Article</td><td>The Annals of pharmacotherapy</td><td>Effectiveness and safety of dorzolamide-timolol alone or combined with latanopro...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16968583/" target="_blank">16968583</a></td><td>2006</td><td>Article</td><td>Current medical research and o</td><td>Comparison of the efficacy and safety of travoprost with a fixed-combination of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32106236/" target="_blank">32106236</a></td><td>2020</td><td>Article</td><td>PloS one</td><td>The efficacy of the fixed combination of latanoprost and timolol versus other fi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20019759/" target="_blank">20019759</a></td><td>2010</td><td>Article</td><td>Eye (London, England)</td><td>Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19348600/" target="_blank">19348600</a></td><td>2009</td><td>Article</td><td>Journal of ocular pharmacology</td><td>A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, eac...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10872922/" target="_blank">10872922</a></td><td>2000</td><td>Article</td><td>Journal of ocular pharmacology</td><td>Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonid...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20558428/" target="_blank">20558428</a></td><td>2010</td><td>Article</td><td>The British journal of ophthal</td><td>The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18640468/" target="_blank">18640468</a></td><td>2008</td><td>Article</td><td>Clinical therapeutics</td><td>Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure,...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. open angle glaucoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.70%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（50 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00333125" target="_blank">NCT00333125</a></td><td>PHASE3</td><td>COMPLETED</td><td>319</td><td>A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01887223" target="_blank">NCT01887223</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Tre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01896180" target="_blank">NCT01896180</a></td><td>PHASE2</td><td>COMPLETED</td><td>63</td><td>A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Lat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00314171" target="_blank">NCT00314171</a></td><td>PHASE3</td><td>COMPLETED</td><td>437</td><td>A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertensio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822081" target="_blank">NCT00822081</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00546286" target="_blank">NCT00546286</a></td><td>PHASE3</td><td>COMPLETED</td><td>170</td><td>A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03257813" target="_blank">NCT03257813</a></td><td>PHASE3</td><td>COMPLETED</td><td>60</td><td>Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00397241" target="_blank">NCT00397241</a></td><td>PHASE4</td><td>COMPLETED</td><td>33</td><td>24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00273455" target="_blank">NCT00273455</a></td><td>PHASE4</td><td>COMPLETED</td><td>34</td><td>Lumigan Versus Cosopt</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00767481" target="_blank">NCT00767481</a></td><td>PHASE3</td><td>TERMINATED</td><td>6</td><td>1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03193333" target="_blank">NCT03193333</a></td><td>PHASE3</td><td>TERMINATED</td><td>51</td><td>A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05857267" target="_blank">NCT05857267</a></td><td>PHASE4</td><td>COMPLETED</td><td>84</td><td>Phase IV, Multicenter, Double-blind, Randomized, Controlled, Parallel-group, Tri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00991822" target="_blank">NCT00991822</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>160</td><td>A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Dis...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00761995" target="_blank">NCT00761995</a></td><td>PHASE4</td><td>COMPLETED</td><td>200</td><td>Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Redu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00576342" target="_blank">NCT00576342</a></td><td>PHASE3</td><td>COMPLETED</td><td>129</td><td>A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Gl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00621335" target="_blank">NCT00621335</a></td><td>N/A</td><td>COMPLETED</td><td>64</td><td>A 12- Week Investigator Masked, Parallel Comparison of Tolerability of Combigan ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01471158" target="_blank">NCT01471158</a></td><td>PHASE4</td><td>COMPLETED</td><td>120</td><td>Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Pati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00957190" target="_blank">NCT00957190</a></td><td>PHASE4</td><td>COMPLETED</td><td>25</td><td>Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctua...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01527682" target="_blank">NCT01527682</a></td><td>PHASE2</td><td>COMPLETED</td><td>37</td><td>Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor f...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01923714" target="_blank">NCT01923714</a></td><td>N/A</td><td>COMPLETED</td><td>103</td><td>Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05973305" target="_blank">NCT05973305</a></td><td>PHASE3</td><td>COMPLETED</td><td>118</td><td>A Randomized, Open-label, Controlled, Comparative Study of Efficacy and Safety o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06883123" target="_blank">NCT06883123</a></td><td>PHASE4</td><td>RECRUITING</td><td>70</td><td>Efficacy and Tolerability of Simbrinza and Rocklatan vs. Cosopt</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02802137" target="_blank">NCT02802137</a></td><td>PHASE4</td><td>COMPLETED</td><td>43</td><td>24-hour Efficacy and Ocular Surface Health With PF Tafluprost and Combined Thera...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00824824" target="_blank">NCT00824824</a></td><td>NA</td><td>COMPLETED</td><td>21</td><td>Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary O...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05973318" target="_blank">NCT05973318</a></td><td>PHASE3</td><td>COMPLETED</td><td>110</td><td>An Open-label, Randomized, Controlled, Comparative Efficacy and Safety Study of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04676126" target="_blank">NCT04676126</a></td><td>PHASE4</td><td>WITHDRAWN</td><td>0</td><td>Augmented Macular Pigment Supplement and Pericentral Visual Function: a Randomiz...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02325518" target="_blank">NCT02325518</a></td><td>PHASE4</td><td>COMPLETED</td><td>218</td><td>The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06369077" target="_blank">NCT06369077</a></td><td>PHASE4</td><td>TERMINATED</td><td>36</td><td>Cross-over Comparison of Latanoprost QOD With Dor-tim QAM to Tim-brim-dor-bim(At...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02053298" target="_blank">NCT02053298</a></td><td>PHASE4</td><td>COMPLETED</td><td>30</td><td>Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822055" target="_blank">NCT00822055</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03966560" target="_blank">NCT03966560</a></td><td>PHASE4</td><td>COMPLETED</td><td>96</td><td>Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Pr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00273442" target="_blank">NCT00273442</a></td><td>PHASE4</td><td>COMPLETED</td><td>60</td><td>Assessing Cosopt Switch Patients</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00545064" target="_blank">NCT00545064</a></td><td>PHASE4</td><td>COMPLETED</td><td>176</td><td>A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Fre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03966365" target="_blank">NCT03966365</a></td><td>PHASE1</td><td>COMPLETED</td><td>24</td><td>Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Preservat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04673604" target="_blank">NCT04673604</a></td><td>NA</td><td>COMPLETED</td><td>42</td><td>Changing From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01340014" target="_blank">NCT01340014</a></td><td>PHASE4</td><td>COMPLETED</td><td>112</td><td>Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00440336" target="_blank">NCT00440336</a></td><td>NA</td><td>UNKNOWN</td><td>30</td><td>Comparison of Efficacy of Prostaglandin Analogues (Xalatan) and Aqueous Suppress...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06177678" target="_blank">NCT06177678</a></td><td>PHASE2</td><td>UNKNOWN</td><td>60</td><td>A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04702789" target="_blank">NCT04702789</a></td><td>PHASE4</td><td>TERMINATED</td><td>28</td><td>Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00815373" target="_blank">NCT00815373</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemod...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01062971" target="_blank">NCT01062971</a></td><td>PHASE2</td><td>COMPLETED</td><td>124</td><td>Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00108017" target="_blank">NCT00108017</a></td><td>PHASE3</td><td>COMPLETED</td><td>330</td><td>Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurna...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01304264" target="_blank">NCT01304264</a></td><td>N/A</td><td>COMPLETED</td><td>35</td><td>Comparison of Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood F...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01145898" target="_blank">NCT01145898</a></td><td>N/A</td><td>COMPLETED</td><td>56</td><td>Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Pros...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00152932" target="_blank">NCT00152932</a></td><td>NA</td><td>UNKNOWN</td><td>17</td><td>Ocular Blood Flow Measured by HRF and CLBF in Newly Diagnosed and Early Glaucoma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00140049" target="_blank">NCT00140049</a></td><td>PHASE4</td><td>COMPLETED</td><td>238</td><td>A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Cen...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00471068" target="_blank">NCT00471068</a></td><td>PHASE4</td><td>TERMINATED</td><td>46</td><td>Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertensi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07335211" target="_blank">NCT07335211</a></td><td>PHASE3</td><td>RECRUITING</td><td>206</td><td>A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical T...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00972257" target="_blank">NCT00972257</a></td><td>PHASE4</td><td>COMPLETED</td><td>64</td><td>Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00273429" target="_blank">NCT00273429</a></td><td>PHASE4</td><td>COMPLETED</td><td>N/A</td><td>Cosopt Versus Xalatan</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26526633/" target="_blank">26526633</a></td><td>2016</td><td>Article</td><td>Ophthalmology</td><td>Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glauc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38985892/" target="_blank">38985892</a></td><td>2024</td><td>Article</td><td>Journal of cataract and refrac</td><td>Open-angle glaucoma and Fuchs dystrophy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39569785/" target="_blank">39569785</a></td><td>2024</td><td>Article</td><td>Vestnik oftalmologii</td><td>[Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40261315/" target="_blank">40261315</a></td><td>2025</td><td>Article</td><td>The Medical letter on drugs an</td><td>Drugs for open-angle glaucoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37425383/" target="_blank">37425383</a></td><td>2023</td><td>Article</td><td>The Malaysian journal of medic</td><td>Comparing the Effectiveness and Adherence between Fixed and Non-Fixed Dorzolamid...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39677168/" target="_blank">39677168</a></td><td>2024</td><td>Article</td><td>Cureus</td><td>Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33217844/" target="_blank">33217844</a></td><td>2020</td><td>Article</td><td>Medicine</td><td>Can dorzolamide/timolol-fixed combination effectively treat primary open-angle g...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34447609/" target="_blank">34447609</a></td><td>2021</td><td>Article</td><td>Journal of drug assessment</td><td>Efficacy and safety of timolol-dorzolamide fixed-combination three times a day v...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17943780/" target="_blank">17943780</a></td><td>2007</td><td>Article</td><td>The Cochrane database of syste</td><td>Medical interventions for primary open angle glaucoma and ocular hypertension.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36453306/" target="_blank">36453306</a></td><td>2022</td><td>Article</td><td>Indian journal of ophthalmolog</td><td>Efficacy of dorzolamide in improving ocular blood flow in patients with open-ang...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28956449/" target="_blank">28956449</a></td><td>2018</td><td>Article</td><td>Drug development and industria</td><td>Dorzolamide nanoliposome as a long action ophthalmic delivery system in open ang...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33397657/" target="_blank">33397657</a></td><td>2022</td><td>Article</td><td>The British journal of ophthal</td><td>Short-term efficacy of latanoprostene bunod for the treatment of open-angle glau...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19929032/" target="_blank">19929032</a></td><td>2009</td><td>Article</td><td>Drugs &amp; aging</td><td>Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32637736/" target="_blank">32637736</a></td><td>2020</td><td>Article</td><td>American journal of ophthalmol</td><td>Netarsudil-associated epithelial keratopathy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27913991/" target="_blank">27913991</a></td><td>2017</td><td>Article</td><td>Advances in therapy</td><td>24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32106236/" target="_blank">32106236</a></td><td>2020</td><td>Article</td><td>PloS one</td><td>The efficacy of the fixed combination of latanoprost and timolol versus other fi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16519552/" target="_blank">16519552</a></td><td>2006</td><td>Article</td><td>PharmacoEconomics</td><td>Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11200308/" target="_blank">11200308</a></td><td>2000</td><td>Article</td><td>Drugs &amp; aging</td><td>Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of ope...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35415266/" target="_blank">35415266</a></td><td>2022</td><td>Article</td><td>BMJ open ophthalmology</td><td>Assessment of the readability and quality of online patient education materials ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12630335/" target="_blank">12630335</a></td><td>2003</td><td>Article</td><td>Drug and therapeutics bulletin</td><td>New topical drugs for open-angle glaucoma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. congestive heart failure</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.61%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38450431/" target="_blank">38450431</a></td><td>2024</td><td>Article</td><td>Expert opinion on drug metabol</td><td>Drug interactions of carbonic anhydrase inhibitors and activators.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14620034/" target="_blank">14620034</a></td><td>2003</td><td>Article</td><td>Canadian journal of ophthalmol</td><td>Prescription of topical antiglaucoma agents for patients with contraindications ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. acute pulmonary heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. respiratory failure</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16879567/" target="_blank">16879567</a></td><td>2006</td><td>Article</td><td>Acta ophthalmologica Scandinav</td><td>Optic nerve pH and PO2: the effects of carbonic anhydrase inhibition, and metabo...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 多張許可證 | 鹽酸多佐胺 | 眼用製劑 | 高眼壓症、廣角性青光眼、開放性青光眼 |

## 安全性考量

- **常見不良反應**：眼部刺痛、苦味、結膜充血
- **禁忌症**：對磺胺類藥物過敏者
- **藥物交互作用**：與其他碳酸酐酶抑制劑併用時需注意累加效應

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
Dorzolamide 的降眼壓機轉在遺傳性青光眼中仍然適用，已有一項兒童先天性青光眼的臨床試驗，
但遺傳性青光眼的特殊性需要更多針對性研究。

**若要推進需要：**
- 針對不同基因突變類型的療效分層研究
- 兒童青光眼長期安全性數據
- 與其他降眼壓藥物的組合治療方案優化


---

## 相關藥物報告

- [Ribavirin]({{ "/drugs/ribavirin/" | relative_url }}) - 證據等級 L3
- [Prednisolone]({{ "/drugs/prednisolone/" | relative_url }}) - 證據等級 L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - 證據等級 L3
- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - 證據等級 L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - 證據等級 L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Dorzolamide老藥新用驗證報告. https://twtxgnn.yao.care/drugs/dorzolamide/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_dorzolamide,
  title = {Dorzolamide老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/dorzolamide/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
